Analyst Ratings for Boston Scientific: Mostly ‘Strong Buy’
On December 8, 2017, Needham & Company upgraded its rating on BSX stock from a "buy" to a "strong buy" and maintained its price target of $32.
On December 8, 2017, Needham & Company upgraded its rating on BSX stock from a "buy" to a "strong buy" and maintained its price target of $32.